Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study
Thomson MJ, Serper M, Khungar V, Weiss LM, Trinh H, Firpi-Morell R, Roden M, Loomba R, Barritt AS, Gazis D, Mospan AR, Fried MW, Reddy KR, Lok AS. Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study. Clinical Gastroenterology And Hepatology 2021, 20: 458-460.e4. PMID: 33775894, PMCID: PMC8464616, DOI: 10.1016/j.cgh.2021.03.031.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseaseFatty liver diseaseLiver diseaseStatin useReal-world cohortCoenzyme reductase inhibitorsHepatic decompensationCardiovascular eventsPatient factorsCardiovascular diseasePatientsLower mortalityReductase inhibitorsStatinsDiseasePrevalenceRiskDecompensationCarcinomaHepatotoxicityCohortMortalityReproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver Diseases
Sarkar M, Brady CW, Fleckenstein J, Forde KA, Khungar V, Molleston JP, Afshar Y, Terrault NA. Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2021, 73: 318-365. PMID: 32946672, DOI: 10.1002/hep.31559.Peer-Reviewed Original Research